Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Jun 1;73(6):645-51.
doi: 10.1001/jamaneurol.2016.0171.

Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease

Affiliations
Multicenter Study

Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease

Kayla M D Cornett et al. JAMA Neurol. .

Abstract

Importance: Disease severity of childhood Charcot-Marie-Tooth disease (CMT) has not been extensively characterized, either within or between types of CMT to date.

Objective: To assess the variability of disease severity in a large cohort of children and adolescents with CMT.

Design, setting, and participants: A cross-sectional study was conducted among 520 children and adolescents aged 3 to 20 years at 8 universities and hospitals involved in the Inherited Neuropathies Consortium between August 6, 2009, and July 31, 2014, in Australia, Italy, the United Kingdom, and the United States. Data analysis was conducted from August 1, 2014, to December 1, 2015.

Main outcomes and measures: Scores on the Charcot-Marie-Tooth Disease Pediatric Scale (CMTPedS), a well-validated unidimensional clinical outcome measure to assess disease severity. This instrument includes 11 items assessing fine and gross motor function, sensation, and balance to produce a total score ranging from 0 (unaffected) to 44 (severely affected).

Results: Among the 520 participants (274 males) aged 3 to 20 years, CMT type 1A (CMT1A) was the most prevalent type (252 [48.5%]), followed by CMT2A (31 [6.0%]), CMT1B (15 [2.9%]), CMT4C (13 [2.5%]), and CMTX1 (10 [1.9%]). Disease severity ranged from 1 to 44 points on the CMTPedS (mean [SD], 21.5 [8.9]), with ankle dorsiflexion strength and functional hand dexterity test being most affected. Participants with CMT1B (mean [SD] CMTPedS score, 24.0 [7.4]), CMT2A (29.7 [7.1]), and CMT4C (29.8 [8.6]) were more severely affected than those with CMT1A (18.9 [7.7]) and CMTX1 (males: 15.3 [7.7]; females: 13.0 [3.6]) (P < .05). Scores on the CMTPedS tended to worsen principally during childhood (ages, 3-10 years) for participants with CMT4C and CMTX1 and predominantly during adolescence for those with CMT1B and CMT2A (ages, 11-20 years), while CMT1A worsened consistently throughout childhood and adolescence. For individual items, participants with CMT4C recorded more affected functional dexterity test scores than did those with all other types of CMT (P < .05). Participants with CMT1A and CMTX1 performed significantly better on the 9-hole peg test and balance test than did those with all other types of CMT (P < .05). Participants with CMT2A had the weakest grip strength (P < .05), while those with CMT2A and CMT4C exhibited the weakest ankle plantarflexion and dorsiflexion strength, as well as the lowest long jump and 6-minute walk test distances (P < .05). Multiple regression modeling identified increasing age (r = 0.356, β = 0.617, P < .001) height (r = 0.251, β = 0.309, P = .002), self-reported foot pain (r = 0.162, β = .114, P = .009), and self-reported hand weakness (r = 0.243, β = 0.203, P < .001) as independent predictors of disease severity.

Conclusions and relevance: These results highlight the phenotypic variability within CMT genotypes and mutation-specific manifestations between types. This study has identified distinct functional limitations and self-reported impairments to target in future therapeutic trials.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None

Figures

Figure 1
Figure 1
Foot alignment frequency measured by the Foot Posture Index (FPI). Dashed curve indicates normative values for unaffected children and young adults. FPI significantly more pes cavus for children and young adults with CMT than normative reference values (p<0.001).
Figure 2
Figure 2
CMTPedS total score differences between CMT subtypes Values are mean ± 95% CI. *Significantly different to CMT1A (p<0.05); aSignificantly different to CMTX1 (p<0.05); bSignificantly different to CMT2A (p<0.05).
Figure 3
Figure 3
CMTPedS item score frequencies A score of 0 indicates <1 SD below normative reference values (unaffected); 1 indicates a score between 1 and 2 SDs below normal (mildly affected); 2 indicates a score between 2 and 3 SDs below normal (moderately affected); 3 indicates a score between 3 and 4 SDs below normal (severely affected); 4 indicates a score > 4 SDs below normal (very severely affected).
Figure 4
Figure 4
CMTPedS scores during childhood and adolescence for CMT subtypes. Individual data points are plotted with linear correlation best fit lines indicating change during childhood (3–10 years) and adolescence (11–20 years).
Figure 5
Figure 5
CMTPedS item z-score differences between CMT subtypes Functional dexterity test and nine hole peg test are timed tests so a positive z-score indicates a longer time and therefore a worse performance. For all other measures a negative z-score indicates a worse performance. *Significantly different to all other types (p<0.05); aSignificantly different to CMT1A, CMT1B, and CMTX1 (p<0.05); bSignificantly different to CMT1A and CMTX1 (p<0.05); cSignificantly different to CMT1B (p<0.05); d Significantly different to CMT1B, CMT2A and CMT4C (p<0.05).

Comment in

References

    1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clinical Genetics. 1974;6(2):98–118. - PubMed
    1. Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot–Marie–Tooth disease. Nature Reviews Neurology. 2013;9(10):562–571. - PubMed
    1. Burns J, Ouvrier R, Estilow T, et al. Validation of the Charcot–Marie–Tooth disease pediatric scale as an outcome measure of disability. Annals of Neurology. 2012;71(5):642–652. - PMC - PubMed
    1. Fridman V, Bundy B, Reilly M, et al. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. Journal of Neurology, Neurosurgery & Psychiatry. 2014;86(8):873–878. - PMC - PubMed
    1. Gonzaga-Jauregui C, Harel T, Gambin T, et al. Exome Sequence Analysis Suggests that Genetic Burden Contributes to Phenotypic Variability and Complex Neuropathy. Cell Reports. 2015;12(7):1169–1183. - PMC - PubMed

Publication types